SEATTLE, WA – Amazon Web Services (AWS) has unveiled Amazon Bio Discovery, a groundbreaking application poised to dramatically accelerate drug…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, has cemented a landmark global research and development…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced an…
Read More
Small Study Suggests Probiotic Yogurt Strain May Boost Immunotherapy Response in Lung Cancer
The landscape of lung cancer treatment has undergone a significant transformation with the advent of immunotherapy, offering renewed hope and…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry grapples with an intractable challenge: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, discussions surrounding drug pricing often commence and conclude with the enigmatic "list…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial.
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth
Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…
Read MoreYOU MAY HAVE MISSED
